Considering the whole population, MYD88 L265P and CD79B Y196 mutations were identified in 38% (14/37) and 30% (11/37) of PCNSL tumors, respectively (Figure 3A), representing the most recurrently mutated genes in our series. This evidence concerns the gene CD79B and primary central nervous system lymphoma.